The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
S Mustafa, CS Jansen, Y Jani, S Evans… - Biomarker …, 2024 - journals.sagepub.com
In the past decade, immune checkpoint inhibitors (ICI) have been approved for treatment of
genitourinary malignancies and have revolutionized the treatment landscape of these …
genitourinary malignancies and have revolutionized the treatment landscape of these …
Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma
SA Berg, MD Galsky - Journal of Clinical Oncology, 2024 - ascopubs.org
Despite decades of research, the oncology community has faced significant challenges in
establishing robust evidence for the role of perioperative chemotherapy for the treatment of …
establishing robust evidence for the role of perioperative chemotherapy for the treatment of …
Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
UM Vogl, I Testi, M De Santis - European Urology Focus, 2024 - europepmc.org
Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is
even more efficient when nivolumab is added. The well-known side-effect profile and the …
even more efficient when nivolumab is added. The well-known side-effect profile and the …
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
J Bellmunt, R Nadal - Med, 2024 - Elsevier
The EV-302 study 1 marks a pivotal leap in the management of advanced urothelial
carcinoma, setting a new benchmark for frontline therapy. Enfortumab vedotin plus …
carcinoma, setting a new benchmark for frontline therapy. Enfortumab vedotin plus …